Yüklüyor......
Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer
OBJECTIVE: Romidepsin (FK228) was recently approved by the FDA for the treatment of cutaneous and peripheral T cell lymphoma. We have shown in vitro efficacy of FK228 in ovarian cancer. Here, our goal was to evaluate FK228 combined with cisplatin in ovarian cancer in vitro and in vivo. METHODS: Ovar...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3541411/ https://ncbi.nlm.nih.gov/pubmed/23010348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.09.016 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|